COMPASS Pathways plc (NASDAQ:CMPS) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in COMPASS Pathways plc (NASDAQ:CMPS) by 161.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,700 shares of the company’s stock after purchasing an additional 131,300 shares during the quarter. Renaissance Technologies LLC owned about 0.31% of COMPASS Pathways worth $804,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $43,000. Flagship Harbor Advisors LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth about $43,000. Conservest Capital Advisors Inc. boosted its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in COMPASS Pathways in the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Analyst Upgrades and Downgrades

CMPS has been the topic of several recent analyst reports. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group cut their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.20.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $4.10 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company’s 50-day moving average price is $3.33 and its 200 day moving average price is $4.14. COMPASS Pathways plc has a 52 week low of $2.49 and a 52 week high of $9.63. The stock has a market cap of $379.96 million, a price-to-earnings ratio of -1.86 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). As a group, research analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.